ASCRS Will Request Relief from Off-Label Communication and Drug Compounding Policies in Response to FDA’s Call for Comments on Regulatory Relief

The Food and Drug Administration (FDA) is asking stakeholders to identify existing regulations that could be repealed in response to President Trump’s deregulatory executive orders. The regulatory reform task force for the Department of Health and Human Services for FDA is issuing a Request for Information (RFI) on ways the agency can change current regulations to achieve burden reduction while ensuring public health safety. ASCRS will be submitting comments related to off-label communications and drug compounding.

This RFI is in response to the implementation of President Trump’s Executive Order 13771, “Reducing Regulation and Controlling Regulatory Costs,” which requires two regulations to be eliminated for every new regulation introduced, as well as Executive Order 13777, “Enforcing the Regulatory Reform Agenda,” which mandates that each federal agency must create a task force to identify unnecessary and costly regulations to repeal.

We will keep you updated.